As a reminder, the Akkermansia muciniphila bacterium was discovered for the first time in 2004. It was isolated from the human intestinal microbiota and characterized at the laboratory of Professor Willem M. de Vos (Wageningen University, Netherlands), co-founder of The Akkermansia Company™. Soon after, the team of Professor Patrice D. Cani (UCLouvain, Bruxelles, Belgium), the other co-founder of the company, discovered the beneficial effects of this bacterium.
Akkermansia muciniphila bacteria restores intestinal barrier function, which decreases inflammation and, over time, helps to control fat storage, glucose metabolism and energy expenditure. Better yet, the pasteurization process increases the effectiveness of Akkermansia. In pasteurized form, it is stable, it has a long storage life and is easy to administer to people.
This collaboration has resulted in dozens of scientific publications and a clinical study on human subjects. Results showed that Akkermansia muciniphila has the ability to limit the risk of deterioration of the health (prediabetes, cardiovascular risks). Researchers have observed a decrease of inflammatory markers in liver, insulin resistance or hypercholesterolemia